본문으로 건너뛰기
← 뒤로

Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases.

1/5 보강
Case reports in oncology 📖 저널 OA 100% 2022: 4/4 OA 2023: 4/4 OA 2024: 5/5 OA 2025: 13/13 OA 2026: 34/34 OA 2022~2026 2026 Vol.19(1) p. 284-292 OA
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies.
I · Intervention 중재 / 시술
HDMTX with different dosing strategies
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Both patients tolerated treatment well and continue to do well at follow-up. [CONCLUSION] These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.

Zafar A, Yakubi H, Moskoff B, Alvarez K, Tang A, Tuscano J

📝 환자 설명용 한 줄

[INTRODUCTION] Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow

이 논문을 인용하기

↓ .bib ↓ .ris
APA Zafar A, Yakubi H, et al. (2026). Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases.. Case reports in oncology, 19(1), 284-292. https://doi.org/10.1159/000550253
MLA Zafar A, et al.. "Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases.." Case reports in oncology, vol. 19, no. 1, 2026, pp. 284-292.
PMID 41782706 ↗
DOI 10.1159/000550253

Abstract

[INTRODUCTION] Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS.

[CASE PRESENTATION] We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up.

[CONCLUSION] These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기